Singapore's sovereign wealth fund GIC has increased its investment allocations toward artificial intelligence, with Anthropic and Eli Lilly among the named positions. The fund is watching regulatory and valuation risks in the sector but is moving toward companies that develop or deploy AI technology. GIC manages an estimated $700 billion in assets, making its directional moves a meaningful signal about where large institutional capital is flowing.
When a sovereign wealth fund of GIC's scale publicly commits to a sector, it tends to pull other large institutional allocators in the same direction. Private AI companies like Anthropic gain indirect credibility and valuation support, while publicly traded AI-adjacent names face fresh demand from funds benchmarking against GIC's positioning. Eli Lilly's inclusion signals that AI-in-healthcare is now a standalone investment thesis, not just a tech story.
Next GIC annual report release (typically July): will detail updated portfolio allocations. Anthropic next funding round (no fixed date, but expected within 2025): will set a new private valuation benchmark. Eli Lilly Q2 earnings, ~August 2025: first major read on whether AI-driven drug development is showing up in margins.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block, and the live update timeline (1 update so far).
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief